Virometix to Present Vaccine Development Progress at the Annual World Vaccine Congress Europe 2018 and further conferences

Schlieren, Switzerland (September 27, 2018) – Virometix, the privately held Swiss biotechnology company who is developing a new generation of fully synthetic vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases and cancer, today announced that its CEO, Dr Arin Ghasparian will present during the 19th World Vaccine Congress Europe on October 29, 2018 in Lisbon, Portugal.

The Presentation is entitled «Smarter Vaccine Designs Using Synthetic Virus-Like Particle Technology and Structurally Optimised Antigens».

The presentation will describe Virometix’ unique approach to vaccine design providing examples from its development programs.

Dr Armando Zuniga, Virometix’ Chief Scientific Officer, will present an abstract with preclinical data of its RSV vaccine candidate V-306 at the 11th International Respiratory Syncytial Virus Symposium, which is taking place from October 31 to November 4, 2018 in Asheville, USA. The Abstract is entitled «Structure-based design of a fully synthetic RSV vaccine candidate based on conformationally stabilized epitope mimetics and self-assembling lipopeptides».

An abstract with preclinical proof-of-concept data of its cancer vaccine program will be also presented by Dr Melissa Vrohlings, Senior Scientist, at the Annual World Immunotherapy Congress 2018 from October 29 to 31 in Basel, Switzerland.

Additional upcoming presentations can be found in the News and Events section on our website www.virometix.com.

About Virometix AG

Virometix AG is a privately held biotechnology company developing a new generation of fully synthetic vaccines and immunotherapeutic drugs for the prevention and treatment of infectious diseases and cancer. Fast growing demands, health threats from newly arising complex viral and bacterial pathogens and increasingly stringent requirements for stability, safety and tolerability require new approaches to tackling current and future challenges. Rational molecular design, and Virometix’ proprietary “Synthetic Virus-Like Particle” (SVLP™) and “Synthetic Antigen Mimetics” (SAM™) platforms allow for the rapid production and optimization of vaccine candidates with superior properties in terms of safety, efficacy and stability. Virometix is based in Zurich, Switzerland.

For more information about Virometix AG please visit: http://www.virometix.com/